Union Health Ministry Appoints Dr Rajeev Singh Raghuvanshi As Secretary-Cum-Scientific Director Of IPC

Mumbai, 22 Feb 2021:

 

Union health ministry has appointed Dr Rajeev Singh Raghuvanshi as the new secretary-cum-scientific director of the Indian Pharmacopoeia Commission (IPC).

 

IPC is as an autonomous institution under the Union health ministry established on January 1, 2009.

 

Dr Jai Prakash, secretary cum scientific director (in-charge) was earlier serving as secretary-cum-scientific director of the IPC.

 

Dr Raghuvanshi completed his Bachelors and Masters from IIT-BHU (Formerly IT-BHU), Varanasi and PhD from National Institute of Immunology, New Delhi.

 

His PhD work is in the area of extended release formulation of vaccines, a project conceptualized to help reduce the number of injections required to be given for complete immunization. He has also done ISB-Kellogg Global Advanced Management Progamme.

 

After working for 7 years at National Institute of Immunology, New Delhi, Dr Rajeev moved to join the leading Indian multination pharmaceutical company Ranbaxy Laboratories Ltd. where he worked for development, registration and launch of NDDS, generics and branded generics in various global markets.

 

After having spent 12 years with Ranbaxy Laboratories, Dr Rajeev moved to another Indian multinational, Dr Reddy’s Laboratories Ltd, Hyderabad. In his 11 years of stay with Dr Reddy’s Labs, 1st eight years was in development of 505b(2) NDA products for US market. In this role, he successfully led the CMC team to get 6 products approved in 1st review cycle by US FDA. During this tenure, he had the opportunity of multiple face to face interactions with US FDA which provided in depth understanding of working of global regulatory agencies.

 

Apart from US FDA, Dr Raghuvanshi has also had face to face interactions with regulatory agencies of UK, South Korea, Sweden, Romania etc. Last three years at Dr Reddy’s has been in a different role of establishing an R&D team for markets like India, China, Russia and other emerging markets in the space of pharmaceutical product Innovation/differentiation, registration and launches. He is widely travelled throughout the world and has worked with team members and partners in countries like USA, UK, China, Russia, South Africa, Romania, Sweden, Canada, France, Australia and Japan.

 

Dr Raghuvanshi’s expertise lies in dosage for design and development, mainly in the domain of pharmaceutical innovation. He has been involved in development of different kind of products like oral solids, oral liquids, topicals, injections, nasal sprays, auto-injectors, sublingual, mouth dissolve, extended release and delayed release for global markets. More than 200 products developed by him and his teams are currently being sold in India, US Europe and emerging markets.

 

Dr Raghuvanshi has 14 granted US patents along with more than 250 published PCTs and Indian patents. He has more than 25 publications in peer reviewed journals and has co-authored 6 chapters in books. He has been visiting faculty at NIPER – Hyderabad and IIT-BHU and has taught students of NIPER-Mohali. He is a regular speaker at different International and National conferences on Pharmaceutical Innovation. For his contribution, Dr Reddy’s Labs has twice awarded him with “Dr Reddy’s Excellence Award”.

 

Leadership development has been his passion and many of his team members mentored by him are holding leadership roles in Indian and global pharmaceutical companies. Pharmabiz